Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Up 267.8% in August

Key Points

• Otsuka Holdings experienced a dramatic increase in short interest, rising by 267.8% in August, with total short interest reaching 54,800 shares as of August 31st.
• The stock has an average rating of "Sell" from analysts, with Zacks Research recently upgrading it to a strong sell on August 11th.
• Otsuka's stock is currently trading around $28.63, with a market cap of $30.75 billion and a notable P/E ratio of 0.19.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 54,800 shares, a growth of 267.8% from the August 15th total of 14,900 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 63,600 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 63,600 shares, the short-interest ratio is currently 0.9 days. Currently, 0.0% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Otsuka to a "strong sell" rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Otsuka currently has a consensus rating of "Sell".

Otsuka Stock Performance

Otsuka stock traded down $1.07 on Wednesday, reaching $27.73. The company's stock had a trading volume of 25,673 shares, compared to its average volume of 52,097. The business's fifty day moving average price is $25.67 and its 200 day moving average price is $24.98. The company has a market cap of $29.79 billion and a price-to-earnings ratio of 0.18. Otsuka has a twelve month low of $21.64 and a twelve month high of $32.41.

About Otsuka

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.